Clinical Trials Logo
  1. Home
  2. Synovial Sarcoma
  3. NCT03250325

Study of TBI-1301 (NY-ESO-1 T Cell Receptor Gene Transduced Autologous T Lymphocytes) in Patients With Synovial Sarcoma

Synovial Sarcoma Clinical Trial

Official title:
Multi-center Phase I/II Study of NY-ESO-1 T Cell Receptor Gene Transferred T Lymphocytes in Patients With Synovial Sarcoma

Clinical Trial Summary

The purpose of this study is to evaluate the safety and the efficacy of TBI-1301 for NY-ESO-1 expressing synovial sarcoma when administered following cyclophosphamide pre-treatment.

Clinical Trial Description

Following pre-treatment with cyclophosphamide, NY-ESO-1-specific T cell receptor (TCR) gene transduced T lymphocytes are transferred to human leukocyte antigen (HLA)-A*02:01 or HLA-A*02:06 positive patients with synovial sarcoma expressing NY-ESO-1, which are surgically unresectable and refractory to anthracycline therapy. The primary objective is to evaluate the safety in the phase 1 and the efficacy in the phase 2. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03250325
Study type Interventional
Source Takara Bio Inc.
Contact
Status Completed
Phase Phase 1/Phase 2
Start date September 20, 2017
Completion date March 9, 2022
View Details
See also
  Status Clinical Trial Phase
Terminated NCT03399448 - NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells) Phase 1
Terminated NCT01957709 - Recombinant Interferon Gamma in Treating Patients With Soft Tissue Sarcoma Early Phase 1
Withdrawn NCT04906876 - A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas Phase 2
Active, not recruiting NCT02869217 - Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors Phase 1
Completed NCT01674101 - Effects of Preoperative Physical Therapy in Patients With Lower Extremity Malignancy N/A
Recruiting NCT06094101 - Personalized Vaccination in Fusion+ Sarcoma Patients (PerVision) Phase 1/Phase 2
Terminated NCT03520959 - A Phase 3, Randomized, Double-blind, Placebo-controlled Study For Subjects With Locally-advanced Unresectable or Metastatic Synovial Sarcoma (V943-003, IMDZ-04-1702) Phase 3
Terminated NCT02683148 - DHEA in Synovial Sarcoma Patients Phase 1
Recruiting NCT05642455 - SPEARHEAD-3 Pediatric Study Phase 1/Phase 2
Active, not recruiting NCT04420975 - Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue Sarcoma Phase 1
Recruiting NCT02983539 - Detection of Circulating Tumor Cells in Patients With Sarcomas
Recruiting NCT04028479 - The Registry of Oncology Outcomes Associated With Testing and Treatment
Active, not recruiting NCT03132922 - MAGE-A4ᶜ¹º³²T for Multi-Tumor Phase 1
Terminated NCT04145700 - CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Synovial Sarcoma Phase 1/Phase 2
Completed NCT00004853 - Comparison of Filgrastim and Filgrastim SD/01in Boosting White Cell Counts After Intensive Chemotherapy Phase 1
Suspended NCT06083883 - Phase I/Ib Study of NK Expressing an Affinity-enhanced T-cell Receptor (TCR) Against the NY-ESO-1 Phase 1
Terminated NCT05355753 - A Study to Assess the Safety and Tolerability of CFT8634 in Locally Advanced or Metastatic SMARCB1-Perturbed Cancers, Including Synovial Sarcoma and SMARCB1-Null Tumors Phase 1/Phase 2
Withdrawn NCT05116800 - Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma Phase 2
Recruiting NCT03638206 - Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies Phase 1/Phase 2
Terminated NCT00140855 - A Study of Anti-CTLA-4 Antibody in Patients With Advanced Synovial Sarcoma Phase 2